Project Grant R21CA289152
Award Date
4/10/25
Completion Date
3/31/27
Dollars Obligated
$216K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University is focused on understanding how tumor-associated macrophages regulate anti-tumor immune responses in non-small cell lung cancer (NSCLC). The $234,749 award supports a Phase Ib clinical trial to investigate the combination of the hedgehog inhibitor vismodegib and the PD-L1 inhibitor atezolizumab in patients with metastatic NSCLC. The goal is to better understand how...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $483,556 to the University of New Mexico Health Sciences Center to conduct research on a novel intraperitoneal nano-immune therapy for peritoneal metastases. The project aims to define the mechanisms by which mesoporous silica nanoparticles functionalized with toll-like receptor agonists can eliminate disseminated peritoneal ovarian and colorectal cancer when delivered...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $641,336 over a 5-year period beginning September 1, 2024 to support research on targeting the GARP-TGFβ axis to improve immunotherapy for non-small cell lung cancer (NSCLC). The primary awardee, The Ohio State University, will conduct preclinical studies evaluating an anti-GARP antibody (PIIO-1) to enhance CD8+ T cell function and overcome resistance to immune checkpoint...
This Project Grant award of $695,797.00 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) will fund a multi-disciplinary research program focused on developing T-cell receptor (TCR) therapies for platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The research team, led by the University of California, Los Angeles (UCLA) and including the Children's Hospital of Philadelphia (CHOP), will employ innovative multi-omic tools and bioinformatic...
The National Cancer Institute awarded a $375,134 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Colorado-Denver. The grant supports research to reduce off-target accumulation of chemotherapeutic nanomedicines and improve the efficacy of cancer chemotherapy. Key objectives include characterizing an innate immune response that can limit nanoparticle deposition in healthy tissues, and exploring the potential to utilize this response to enable more...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research on the role of genetic polymorphisms in interleukin-6 (IL-6) and IL-6 receptor (IL-6R) in immune-related adverse events (irAEs) caused by cancer immunotherapy. The $401,115 award will be used to investigate: 1) the effect of IL-6 and IL-6R genetic variations on IL-6 and soluble IL-6R production by human CD4 cells, and 2) the association between these polymorphisms...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic provides $635,946 to conduct research aimed at understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The key objectives are to: Test the hypothesis that UV-induced interferon-I signaling elicits a PD-L1-dependent inflammatory memory in melanoma, impacting tumor immune surveillance and progression. This will...
This Project Grant award in the amount of $639,004 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research on a novel long-acting interleukin-7 (NT-I7) therapy to enhance immune response and improve survival in patients with glioblastoma. The project aims to evaluate the safety and efficacy of combining NT-I7 with anti-PD-1 checkpoint blockade in a Phase II clinical trial, as well as conduct preclinical studies to understand the mechanisms by which NT-I7...
This Project Grant award, with the ID R21CA286410, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The $176,712 award supports research to investigate how tumor-derived heat shock proteins (HSPs) can prime T cell responses and enable cancer immunosurveillance. The research aims to develop a new mouse model to study the role of the CD91 receptor on antigen-presenting cells in providing co-stimulation and cytokines necessary...
This Project Grant award of $210,789 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to evaluate the effectiveness of a novel antisense therapy (termed CDKKMO) targeting the DKK-1 protein in treating osteosarcoma (OS) in dogs. The research aims to empirically characterize the molecular mechanisms governing the effects of DKK-1 inhibition on OS tumor progression, metastasis, and bone destruction in canine OS cell lines and patient-derived...